The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
 
David Michael Hyman
No Relationships to Disclose
 
Theodore Willis Laetsch
No Relationships to Disclose
 
Shivaani Kummar
No Relationships to Disclose
 
Steven G. DuBois
No Relationships to Disclose
 
Anna F. Farago
No Relationships to Disclose
 
Alberto S. Pappo
No Relationships to Disclose
 
George D. Demetri
No Relationships to Disclose
 
Wafik S. El-Deiry
No Relationships to Disclose
 
Ulrik Niels Lassen
No Relationships to Disclose
 
Afshin Dowlati
No Relationships to Disclose
 
Marcia S. Brose
No Relationships to Disclose
 
Valentina Boni
No Relationships to Disclose
 
Brian Turpin
No Relationships to Disclose
 
Ramamoorthy Nagasubramanian
No Relationships to Disclose
 
Scott Cruickshank
No Relationships to Disclose
 
Michael Craig Cox
No Relationships to Disclose
 
Nora C. Ku
No Relationships to Disclose
 
Douglas S. Hawkins
No Relationships to Disclose
 
David S. Hong
No Relationships to Disclose
 
Alexander E. Drilon
No Relationships to Disclose